Patents by Inventor Luc Montagnier

Luc Montagnier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20030235835
    Abstract: A method for diagnosing an HIV-2 (LAV-II) infection and a kit containing reagents for the same is disclosed. These reagents include cDNA probes which are capable of hybridizing to at least a portion of the genome of HIV-2. In one embodiment, the DNA probes are capable of hybridizing to the entire genome of HIV-2. These reagents also include polypeptides encoded by some of these DNA sequences.
    Type: Application
    Filed: November 25, 2002
    Publication date: December 25, 2003
    Applicant: Institut Pasteur
    Inventors: Marc Alizon, Luc Montagnier, Denise Guetard, Francois Clavel, Pierre Sonigo, Mireille Guyader
  • Patent number: 6664041
    Abstract: The invention relates to a new class of retroviruses, designated by HIV-2, of which samples have been deposited to the ECACC under numbers 87.01.1001 and 87.01.1002 and to the NCIB under numbers 12.398 and 12.399. It relates also to antigens capable to be obtained from this virus, particularly proteins p12, p16, p26 and gp140. These various antigens can be used for the diagnosis of the disease, especially by contacting these antigens with a serum of a patient submitted to the diagnosis. It relates to immunogenic compositions containing more particularly the glycoprotein gp140. Finally it concerns nucleotidic sequences, which can be used especially as hybridization probes, derived from the RNA of HIV-2.
    Type: Grant
    Filed: May 23, 2001
    Date of Patent: December 16, 2003
    Assignee: Institut Pasteur
    Inventors: Luc Montagnier, Solange Chamaret, Denise Guetard, Marc Alizon, François Clavel, Mireille Guyader, Pierre Sonigo, Françoise Brun-Vezinet, Marianne Rey, Christine Rouzioux, Christine Katlama
  • Publication number: 20030224352
    Abstract: A variant of a LAV virus, designated LAVMAL and capable of causing AIDS. The cDNA and antigens of the LAVMAL virus can be used for the diagnosis of AIDS and pre-AIDS.
    Type: Application
    Filed: April 17, 2003
    Publication date: December 4, 2003
    Applicant: Institut Pasteur
    Inventors: Marc Alizon, Pierre Sonigo, Simon Wain-Hobson, Luc Montagnier
  • Patent number: 6635752
    Abstract: A variant of a LAV virus, designated LAVMAL and capable of causing AIDS. The cDNA and antigens of the LAVMAL virus can be used for the diagnosis of AIDS and pre-AIDS.
    Type: Grant
    Filed: April 16, 2001
    Date of Patent: October 21, 2003
    Assignee: Institut Pasteur
    Inventors: Marc Alizon, Pierre Sonigo, Simon Wain-Hobson, Luc Montagnier
  • Publication number: 20030186219
    Abstract: A method for diagnosing an HIV-2 (LAV-II) infection and a kit containing reagents for the same is disclosed. These reagents include cDNA probes which are capable of hybridizing to at least a portion of the genome of HIV-2. In one embodiment, the DNA probes are capable of hybridizing to the entire genome of HIV-2. These reagents also include polypeptides encoded by some of these DNA sequences.
    Type: Application
    Filed: November 9, 2001
    Publication date: October 2, 2003
    Applicant: Institut Pasteur of Paris
    Inventors: Marc Alizon, Luc Montagnier, Denise Guetard, Francoise Brun-Vezinet, Francois Clavel
  • Patent number: 6627395
    Abstract: The identification, separation, purification, and propagation of the HIV-1 virus is provided. Moreover, the preparation of antigens from HIV-1 is further provided. The identification of HIV-1 involves the purification of a virus sample from lymphocytes and contacting the sample with antibodies, which bind to HIV-1 viruses, is provided. The propagation of HIV-1 virus involves infecting uninfected T lymphocytes with the virus. Moreover, the preparation of antigens from HIV-1 involves the separation of protein components of a purified HIV-1 virus under denaturing conditions.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: September 30, 2003
    Assignees: Institut Pasteur, The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Luc Montagnier, Jean-Claude Chermann, Francoise Barre-Sinoussi, Francoise Brun-Vezinet, Christine Rouzioux, Willy Rozenbaum, Charles Dauguet, Jacqueline Gruest, Marie-Therese Nugeyre, Francoise Rey, Claudine Axler-Blin, Solange Chamaret, Robert C. Gallo, Mikulas Popovic, Mangalasseril G. Sarngadharan
  • Publication number: 20030170658
    Abstract: The invention relates to a new class of retroviruses, designated by HIV-2, of which samples have been deposited to the ECACC under numbers 87.01.1001 and 87.01.1002 and to the NCIB under numbers 12.398 and 12.399.
    Type: Application
    Filed: June 27, 2002
    Publication date: September 11, 2003
    Applicant: Institut Pasteur
    Inventors: Luc Montagnier, Solange Chamaret, Denise Guetard, Marc Alizon, Francois Clavel, Mireille Guyader, Pierre Sonigo, Francoise Brun-Vezinet, Marianne Rey, Christine Rouzioux, Christine Katlama
  • Patent number: 6608179
    Abstract: Characterization of the envelope transmembrane protein of human immunodeficiency virus type 2 (HIV-2) was carried out using murine polyclonal and monoclonal antibodies or patient sera specific for HIV-2 proteins. A 80-Mr glycoprotein (gp80) was produced in HIV-2 infected cells along with three other glycoproteins that were recently reported: the extracellular glycoprotein (gp125), the envelope glycoprotein precursor (gp140), and the transient dimeric form of gp140 (gp300). The gp125 and gp80 were detectable after the synthesis of gp140 and the formation of gp300. Among these four glycoproteins, only gp80 and gp125 were associated with HIV-2 virions. As the other glycoproteins, gp80 was recognized by all HIV-2 positive sera. A murine polyclonal antibody raised against the purified gp300 recognized all four glycoproteins.
    Type: Grant
    Filed: September 22, 1999
    Date of Patent: August 19, 2003
    Assignee: Institut Pasteur
    Inventors: Ara G. Hovanessian, Marie-Anne Rey, Anne G. Laurent, Bernard Krust, Luc Montagnier
  • Patent number: 6600023
    Abstract: Antibodies which bind with antigens of human immunodeficiency virus type 1 (HIV-1), such as Lymphadenopathy Associated Virus (LAV), are disclosed. Retroviruses associated with Acquired Immune Deficiency Syndrome (AIDS) are isolated from the sera of patients afflicted with Lymphadenopathy Syndrome (LAS) or AIDS. Viral extracts, structural proteins and other fractions of the retrovirus immunologically recognize the sera of such patients.
    Type: Grant
    Filed: February 18, 1993
    Date of Patent: July 29, 2003
    Assignees: Institut Pasteur, The United States of America as represented by the Department of Health and Human Services
    Inventors: Luc Montagnier, Jean-Claude Chermann, Francoise Barre-Sinoussi, Francoise Brun-Vezinet, Christine Rouzioux, Willy Rozenbaum, Charles Dauguet, Jacqueline Gruest, Marie-Therese Nugeyre, Francoise Rey, Claudine Axler-Blin, Solange Chamaret, Robert C. Gallo, Mikulas Popovic, Mangalasseril G. Sarngadharan
  • Publication number: 20030091985
    Abstract: A method for diagnosing an HIV-2 (LAV-II) infection and a kit containing reagents for the same is disclosed. These re-agents include cDNA probes which are capable of hybridizing to at least a portion of the genome of HIV-2. In one embodiment, the DNA probes are capable of hybridizing to the entire genome of HIV-2. These reagents also include polypeptides encoded by some of these DNA sequences.
    Type: Application
    Filed: November 19, 2001
    Publication date: May 15, 2003
    Applicant: Institut Pasteur
    Inventors: Marc Alizon, Luc Montagnier, Denise Guetard, Francois Clavel, Pierre Sonigo, Mireille Guyader
  • Publication number: 20030082523
    Abstract: A method for diagnosing an HIV-2 (LAV-II) infection and a kit containing reagents for the same is disclosed. These reagents include cDNA probes which are capable of hybridizing to at least a portion of the genome of HIV-2. In one embodiment, the DNA probes are capable of hybridizing to the entire genome of HIV-2. These reagents also include polypeptides encoded by some of these DNA sequences.
    Type: Application
    Filed: April 29, 2002
    Publication date: May 1, 2003
    Applicant: Institut Pasteur
    Inventors: Marc Alizon, Luc Montagnier, Denise Guetard, Francois Clavel, Pierre Sonigo, Mireille Guyader
  • Patent number: 6544728
    Abstract: A method for diagnosing an HIV-2 (LAV-II) infection and a kit containing reagents for the same is disclosed. These reagents include cDNA probes which are capable of hybridizing to at least a portion of the genome of HIV-2. In one embodiment, the DNA probes are capable of hybridizing to the entire genome of HIV-2. These reagents also include polypeptides encoded by some of these DNA sequences.
    Type: Grant
    Filed: December 20, 1991
    Date of Patent: April 8, 2003
    Assignee: Institut Pasteur
    Inventors: Marc Alizon, Luc Montagnier, Denise Guétard, Francois Clavel, Pierre Sonigo, Mireille Guyader
  • Publication number: 20030049604
    Abstract: An HIV-1 type (or subtype) O retrovirus protein, or a natural or synthetic polypeptide or peptide including at least a part of said protein, which is capable of being recognised by antibodies isolated from a serum resulting from infection by an HIV-1 type O VAU strain or an HIV-1 type (or subtype) O DUR strain.
    Type: Application
    Filed: December 27, 2001
    Publication date: March 13, 2003
    Applicant: Institut Pasteur
    Inventors: Pierre Charneau, Francois Clavel, Andrew Borman, Caroline Quillent, Denise Guetard, Luc Montagnier, Jacqueline Donjon De Saint-Martin, Jacques H.M. Cohen
  • Patent number: 6518015
    Abstract: This invention includes a peptide comprising the sequence CAFRQVC and an antigenic composition using the same. It also includes an in vitro method of detecting HIV-1 and HIV-2 antibodies in a sample using the peptide, and a kit for carrying out the method.
    Type: Grant
    Filed: May 12, 2000
    Date of Patent: February 11, 2003
    Assignee: Institut Pasteur
    Inventors: Marc Alizon, Luc Montagnier, Denise G Guétard, Francois Clavel, Pierre Sonigo, Mireille Guyader
  • Patent number: 6514691
    Abstract: This invention is directed toward the isolation of a novel retrovirus, the human immune deficiency virus type 2 (HIV-2, previously named LAV-2), from patients with acquired immune deficiency syndrome (AIDS) originating from West Africa. This virus is related to HIV-1, the causative agent of AIDS, both by its morphology and by its tropism and in vitro cytopathic effect on CD4 (T4) positive cell lines and lymphocytes. However, preliminary hybridization experiments indicated that there are substantiated differences between the sequences of the two genomes. Furthermore, the proteins of HIV-1 and HIV-2 have different sizes and their serological cross-reactivity is restricted to the major core protein, as the envelope glycoproteins of HIV-2 are not immunoprecipitated by HIV-1 positive sera. Overlapping molecular clones were obtained and the complete nucleotide sequence of the gag and env genes was ascertained.
    Type: Grant
    Filed: November 13, 1998
    Date of Patent: February 4, 2003
    Assignee: Institut Pasteur
    Inventors: Marc Alizon, Luc Montagnier, Denise Guetard, Francois Clavel, Pierre Sonigo, Mireille Guyader
  • Publication number: 20020177128
    Abstract: A variant of a LAV virus, designated LAVMAL and capable of causing AIDS. The cDNA and antigens of the LAVMAL virus can be used for the diagnosis of AIDS and pre-AIDS.
    Type: Application
    Filed: February 19, 2002
    Publication date: November 28, 2002
    Applicant: Institut Pasteur
    Inventors: Marc Alizon, Pierre Sonigo, Simon Wain-Hobson, Luc Montagnier
  • Publication number: 20020168628
    Abstract: A variant of a LAV virus, designated LAVMAL and capable of causing AIDS. The cDNA and antigens of the LAVMAL virus can be used for the diagnosis of AIDS and pre-AIDS.
    Type: Application
    Filed: December 18, 2001
    Publication date: November 14, 2002
    Applicant: Institut Pasteur of Paris
    Inventors: Marc Alizon, Pierre Sonigo, Simon Wain-Hobson, Luc Montagnier
  • Publication number: 20020169112
    Abstract: Methods of treating, and pharmacological formulations and administration methods for treating, mycoplasma-like organism infections in pathological situations. Combinations of antibiotics, targeting different mycoplasma metabolic pathways, are combined with antioxidants to reduce oxidative stresses. This treatment improves host cell resistance to oxidative stress while reducing mycoplasma infection levels.
    Type: Application
    Filed: May 7, 2002
    Publication date: November 14, 2002
    Inventor: Luc Montagnier
  • Patent number: 6428952
    Abstract: Retroviruses associated with Acquired Immune Deficiency Syndrome (AIDS), including Lymphadenopathy Associated Virus (LAV), are isolated from the sera of patients afflicted with Lymphadenopathy Syndrome (LAS) or AIDS. LAV is a Human Immunodeficiency Virus (HIV). Viral extract, structural proteins and other fractions of the retrovirus immunologically recongize the sera of such patients. Immunological reaction is used to detect antibodies that specifically bind to antigenic sites of the retrovirus in samples of body fluids from patients with AIDS or risk of AIDS.
    Type: Grant
    Filed: April 19, 1995
    Date of Patent: August 6, 2002
    Assignees: Institut Pasteur, The United States of America as represented by the Department of Health and Human Services
    Inventors: Luc Montagnier, Jean-Claude Chermann, Francoise Barre-Sinoussi, Francoise Brun-Vezinet, Christine Rouzioux, Willy Rozenbaum, Charles Dauguet, Jacqueline Gruest, Marie-Therese Nugeyre, Francoise Rey, Claudine Axler-Blin, Solange Chamaret, Robert C. Gallo, Mikulas Popovic, G. Sarngadharan
  • Patent number: 6429306
    Abstract: The present invention is directed toward a novel human retrovirus isolated from West African AIDS patients. This virus was originally designated lymphadenopathy associated virus (LAV) type II and subsequently renamed the human immunodeficiency virus type 2, or HIV-2. This virus is genotypically and phenotypically distinct from both human immunodeficiency virus type 1 (HIV-1) and the simian immunodeficiency virus (SIV). A recombinant &lgr; phage library was prepared by subjecting HIV-2-infected CEM genomic DNA to digestion with Sau3AI. The library was screened with an HIV-2-specific cDNA probe and molecular clones of the virus were obtained. Restriction maps and the nucleotide sequences of these clones were ascertained. These nucleic acids should prove useful, inter alia, as probes for the detection of HIV-2 in biological samples and for the expression of HIV-2 gene products.
    Type: Grant
    Filed: February 22, 1995
    Date of Patent: August 6, 2002
    Assignee: Institut Pasteur
    Inventors: Luc Montagnier, Denise Guetard, Marc Alizon, François Clavel, Mireille Guyader, Pierre Sonigo, Françoise Brun-Vezinet